Top-to-Bottom Collaboration - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Top-to-Bottom Collaboration
To continue innovating, the biopharmaceutical sector needs support from all levels.

Pharmaceutical Technology
Volume 34, Issue 7, pp. 120, 119

The Congressional Budget Office stated in a 2006 report on R&D that, "The pharmaceutical industry is one of the most research-intensive industries in the United States. Pharmaceutical firms invest as much as five times more in research and development, relative to their sales, than the average US manufacturing firm."

However, as we look to the future and work to promote the sustainable growth of the sector, we know that challenges remain. We believe that one of the best ways to achieve sustainable growth is through collaboration. The combination of federal and state funding in medical research along with substantial private investment—and the public-private partnerships that follow—are an important way to foster economic growth at the state and regional levels.

Many states have implemented a range of policies and programs in recent years to help attract and grow jobs in the biopharmaceutical sector, providing an important economic counterpoint to the national programs in countries outside the United States intended to woo America's biopharmaceutical companies. From tax credits to the development of technology parks in collaboration with university systems, these efforts have helped create innovation clusters that lead to job growth and the stimulation of local economies.

Unfortunately, as the report commissioned by CAMI points out, although the US was one of the first countries to offer an R&D tax credit beginning in 1981, we have not kept up with the efforts made by other countries. It is time our national policymakers follow suit with the many successful state efforts that have stimulated the biopharmaceutical sector, along with America's other innovative industries.

These programs, which could promote private investment, inform regulatory policy, advocate translational research and public-private partnerships, and develop scientific talent through improved educational platforms, would enhance the work of biopharmaceutical research companies. The benefit to both America's patients and to America's economy could, as we rebuild, be immeasurable.

Ken Johnson is senior vice-president of the Pharmaceutical Research and Manufacturers of America (PhRMA).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here